Back to News
Market Impact: 0.1
Intellia Therapeutics Names New CMO To Oversee Clinical And Regulatory Functions
Source: Nasdaq
Management & GovernanceHealthcare & Biotech
Intellia Therapeutics appointed Jing L. Marantz, M.D., Ph.D., as executive vice president and chief medical officer, effective October 26, 2026. The report provides no further details on strategy, financial impact, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
NTLA0.10
More News
- FBI arrests OpenAI employee accused of planting secret recording device in conference room
- How tech icon Meg Whitman is already leaving her mark on grocery giant Albertsons
- J&J's 6% slide on an imperfect quarter is a gift to prospective buyers
- UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costs
- Liquidia (NASDAQ:LQDA) CMO Rajeev Saggar disposes of $262,528 in stock
- Rhythm Pharmaceuticals launches IMCIVREE in Japan for obesity
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More
- AI Software for Buy-Side Teams: Build the Research Stack